(Alliance News) - MaxCyte Inc on Wednesday said it has signed a strategic platform licence with TG Therapeutics Inc to develop its autoimmune cell therapy. Read More
(Alliance News) - MaxCyte Inc on Thursday said it has acquired SeQure Dx Inc, as it looks to improve its gene therapy testing process. Read More
(Alliance News) - MaxCyte Inc on Monday raised its 2024 revenue guidance above initial expectations, and above the updated guide reported in December. Read More
(Alliance News) - MaxCyte Inc on Monday said the current year has been good for the company as it upgraded its core revenue guidance for 2024 and anticipates cost savings for 2025. Read More
(Alliance News) - MaxCyte Inc on Thursday said profit fell in the third quarter despite revenue growth, as costs increase more than 80%. Read More
(Alliance News) - MaxCyte Inc on Monday celebrated the signing of a strategic platform license agreement with Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company. Read More
(Alliance News) - MaxCyte Inc on Wednesday said loss narrowed in the first half amid growing revenue and the signing of new partnership agreements. Read More
MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies - Says Chief Executive Officer Maher Masoud acquired 100,000 shares in the company between Friday and Monday. Masoud purchased the shares at an average of 489.07 US cents each in New York on the open market. These comprise his entire shareholding so far in MaxCyte, giving him an approximate 0.1% stake. Masoud, who became CEO in January, also holds a further 1.1 million options over MaxCyte's common stock and 400,000 performance stock units. Read More
MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Inks strategic platform license agreement with Legend Biotech Corp, a firm focused in cell therapy. Under the terms of the agreement, Legend Biotech will get a non-exclusive worldwide license to use MaxCyte's Flow Electroporation technology and ExPERT platform in connection with the research, clinical development and commercialisation of cell-based therapeutical products. Accordingly, MaxCyte will be allowed to receive annual licensing fees and milestones from Legend during clinical development. Read More
(Alliance News) - MaxCyte Inc on Wednesday reported a jump in its first quarter revenue, which it said was driven by its core business sales. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Net loss widens to USD37.9 million in 2023 from USD23.6 million in 2022, as revenue declines by 6.7% to USD41.3 million from 44.3 million. Core business revenue falls by 25% to USD29.8 million from USD39.6 million, but strategic platform license programme-related revenue more than doubles to USD11.5 million from USD4.6 million. In the fourth quarter alone, revenue is USD15.7 million, up 26% from USD12.4 million a year before, as core business revenue falls by 32% but SPL revenue more than quadruples. Read More
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Signs strategic platform licence with Wugen Inc, a US-based clinical-stage biotech company developing off-the-shelf cell therapies for the treatment of hematological and solid cancer tumour malignancies. Wugen's lead program is evaluating WU-CART-007, a cell therapy for the treatment of relapsed or refractory T-cell acute lymphoblastic leukaemia. Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte's unique Flow electroporation technology and its trademarked ExPERT research platform. In exchange, MaxCyte will receive annual licence fees and programme-related revenue, although precise transaction details were not provided. Read More